Pascale Khairallah1, Thomas L Nickolas2. 1. Division of Nephrology, Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH2-124, New York City, NY, 10032, USA. 2. Division of Nephrology, Department of Medicine, Columbia University Medical Center, 622 West 168th Street, PH2-124, New York City, NY, 10032, USA. tln2001@cumc.columbia.edu.
Abstract
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is associated with bone loss and fractures. The purpose of this review is to provide clinicians with an overview of the underlying pathogenesis of CKD-associated osteoporosis, and a summary of the current diagnostic and therapeutic approaches to this disease. RECENT FINDINGS: In 2017, the Kidney Disease Improving Global Outcomes Committee on Bone Quality updated their guidelines to include screening for osteoporosis and fracture risk by dual energy X-ray absorptiometry in patients with CKD. Once a diagnosis of osteoporosis and/or fracture risk is established, it is not clear how nephrologists should manage their patients. Patients with CKD should be screened for CKD-associated osteoporosis and considered for strategies that prevent bone loss and fractures. Assessment of bone turnover via imaging, biochemical testing, or bone biopsy can help guide the choice of therapy. Randomized controlled trials are needed to assess safety and efficacy of treatments to prevent bone loss and fractures.
PURPOSE OF REVIEW: Chronic kidney disease (CKD) is associated with bone loss and fractures. The purpose of this review is to provide clinicians with an overview of the underlying pathogenesis of CKD-associated osteoporosis, and a summary of the current diagnostic and therapeutic approaches to this disease. RECENT FINDINGS: In 2017, the Kidney Disease Improving Global Outcomes Committee on Bone Quality updated their guidelines to include screening for osteoporosis and fracture risk by dual energy X-ray absorptiometry in patients with CKD. Once a diagnosis of osteoporosis and/or fracture risk is established, it is not clear how nephrologists should manage their patients. Patients with CKD should be screened for CKD-associated osteoporosis and considered for strategies that prevent bone loss and fractures. Assessment of bone turnover via imaging, biochemical testing, or bone biopsy can help guide the choice of therapy. Randomized controlled trials are needed to assess safety and efficacy of treatments to prevent bone loss and fractures.
Authors: Catarina Carvalho; J Magalhães; R Neto; L Pereira; P Branco; T Adragão; J M Frazão Journal: J Bone Miner Metab Date: 2016-11-09 Impact factor: 2.626
Authors: Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi Journal: J Bone Miner Res Date: 2012-08 Impact factor: 6.741
Authors: Areef Ishani; Terri Blackwell; Sophie A Jamal; Steven R Cummings; Kristine E Ensrud Journal: J Am Soc Nephrol Date: 2008-04-09 Impact factor: 10.121
Authors: Daniel W Coyne; Seth Goldberg; Mark Faber; Cybele Ghossein; Stuart M Sprague Journal: Clin J Am Soc Nephrol Date: 2014-06-26 Impact factor: 8.237
Authors: Ken Iseri; Abdul Rashid Qureshi; Jonaz Ripsweden; Olof Heimbürger; Peter Barany; Ingrid B Bergström; Peter Stenvinkel; Torkel B Brismar; Bengt Lindholm Journal: J Bone Miner Metab Date: 2020-09-04 Impact factor: 2.626
Authors: Shirley Ferraz Crispilho; Eduardo Jorge Duque; Kalyanna Soares Bezerra; Rosa Maria R Pereira; Vanda Jorgetti; Rosilene M Elias; Rosa M A Moysés Journal: J Bras Nefrol Date: 2021 Apr-Jun